Why the study?
Does SGLT2i therapy reduce hospitalization for non-rheumatic aortic valve disease in diabetic patients compared to sulphonylureas?
Population
60,344 diabetic patients from the Lombardy regional healthcare database starting second-line therapy…
Comparison
Sodium-glucose co-transporter 2 inhibitors as… vs Sulphonylureas (SU) as second-line therapy.
Design
Cohort
Follow-up
24 months
Authors
Loading...
SGLT2i merit study in AS; leaves open any effect on progression or outcomes.
Does SGLT2i therapy reduce hospitalization for non-rheumatic aortic valve disease in diabetic patients compared to sulphonylureas?
SGLT2 inhibitors are associated with a 40% lower rate of hospitalization for aortic valve disease compared to sulfonylureas in diabetic patients, a protective effect potentially mediated by SIRT1-dependent reduction in fibro-calcific processes.
Valerio et al. (2025) studied this question.